GENERICS AND BIOSIMILARS INITIATIVE JOURNAL
Official Journal of the Generics and Biosimilars Initiative
Volume 2 / Year 2013 / Issue 3
Commentary
Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency; influence and future directions
Author(s): Brian Godman, BSc, PhD
Page: 112-3Abstract: Dr Brian Godman reviews the paper by Markovic-Pekovic et al. regarding recent reforms in the Republic of Srpska. These include prescribing restrictions where concerns with the value of products and measures to obtain low prices for generics, which is important given the rhetoric. Submitted: 11 June 2013; Revised: 13 June 2013; Accepted: 17 June […]
Biosimilar monoclonal antibodies—challenges and opportunities in Europe
Author(s): Professor Andrea Laslop, MD
Page: 110-1Abstract: New regulations for the development of biosimilars have been introduced in Europe and a new class of biosimilars – monoclonal antibodies – is expected on the market soon, which will both challenge and benefit our healthcare systems. Submitted: 3 June 2013; Revised: 16 July 2013; Accepted: 23 July 2013; Published online first: 5 August […]
Commentary on the recommendations of the European Society for Organ Transplantation Advisory Committee on generic substitution of immunosuppressive drugs
Author(s): Professor Teun van Gelder, MD, PhD
Page: 108-9Abstract: In 2010, the Council of the European Society for Organ Transplantation formed an Advisory Committee to formulate recommendations on the use of generic drugs in solid organ transplant recipients. The initiative was taken as a result of concerns regarding generic substitution of immunosuppressive drugs. The recommendations were published in Transplant International, and this paper […]
